FDA approves Taxotereinjection for cancer

Sanofi-Aventis announced that the US Food and Drug Administration (FDA) had approved Taxotere (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil (TPF regimen), for induction therapy of locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) before patients undergo chemoradiotherapy and surgery, said a press release.
The FDA based its approval on the results of the phase III randomised, open-label, international trial, TAX 324, which established the efficacy and safety of the Taxotere-based regimen in significantly improving survival.